LivaNova (NASDAQ:LIVN) Cut to "Buy" at StockNews.com

LivaNova (NASDAQ:LIVN - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Saturday.

Other research analysts also recently issued reports about the stock. Robert W. Baird boosted their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Stifel Nicolaus boosted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They set a "buy" rating and a $65.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $69.17.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded down $0.22 on Friday, hitting $52.10. 357,203 shares of the company were exchanged, compared to its average volume of 618,280. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The stock's 50 day moving average price is $51.77 and its 200 day moving average price is $52.95. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.83 billion, a P/E ratio of 124.05 and a beta of 1.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its stake in shares of LivaNova by 4.7% during the first quarter. ProShare Advisors LLC now owns 12,378 shares of the company's stock worth $692,000 after purchasing an additional 561 shares in the last quarter. Entropy Technologies LP purchased a new stake in shares of LivaNova during the first quarter worth about $295,000. State Board of Administration of Florida Retirement System increased its stake in shares of LivaNova by 13.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 17,542 shares of the company's stock worth $981,000 after purchasing an additional 2,060 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company's stock worth $102,537,000 after purchasing an additional 62,480 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of LivaNova during the first quarter worth about $94,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.